68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients

Summary

Based on the high expression of specific receptors on the surface of diseased tissues and neovascularization, noninvasive targeted molecular imaging can be used to visualize lesions in vitro by combining specific ligands labeled with short half-life isotopes. Lung cancer tissues express fibroblast activating protein FAP, and also have high expression of integrin αVβ3 receptor on the surface of blood vessels. In this study, a novel dual-target imaging agent 68Ga-FAPI-RGD was used for PET/CT imaging of lung cancer.

Eligibility

Inclusion Criteria:

* patients with confirmed or suspected lung cancer;
* 68Ga-FAPI-RGD and 18F-FDG(or 68Ga-FAPI or 68Ga-RGD) PET/CT within 2 week;
* signed written consent.

Exclusion Criteria:

* pregnancy;
* breastfeeding;
* any medical condition that in the opinion of the investigator may significantly interfere with study compliance.

Conditions3

Interventions4

Related trials

• 68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients — Peking Union Medical College Hospital
• A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma — Peking University First Hospital
• CD147 Targeting Nanobody Probe for PET Imaging in Solid Tumors — Hua Zhu
• CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors — Peking University Cancer Hospital & Institute
• Dosimetry and Preliminary Clinical Application Study of a Novel Probe Targeting CD73 — First Affiliated Hospital of Fujian Medical University
• Lung Nodule Detection Using Ultra-long FOV PET/CT — University Medical Center Groningen
• Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma — Peking University Cancer Hospital & Institute
• PD-L1 Specific [68Ga]Ga-THP-PDL1-3 Probe for PET Imaging in Solid Tumors — Hua Zhu

Browse More Trials